Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 152,154

Document Document Title
WO/2018/187499A1
Disclosed herein are stable peptide antagonists based on the consensus yc-subunit binding site to inhibit the activity of yc-cytokines. Such peptide antagonists are capable of inhibiting the activity of multiple yc-cytokine family member...  
WO/2018/186487A1
Provided is adenosine as a substance that induces attracting behavior and food searching behavior of fish. Also provided is a novel adenosine receptor as a receptor for adenosine.  
WO/2018/184188A1
Provided are a live recombinant Mycobacterium bovis-BCG strain and a tuberculosis (TB) vaccine or immunogenic composition comprising a nucleic acid capable of overexpression, the nucleic acid encoding PhoP and PhoR proteins. A method for...  
WO/2018/184964A1
The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules e...  
WO/2018/187746A1
Described herein are compositions comprising osteopontin (OPN) or an antigenic fragment thereof and a protein carrier and uses of the compositions to treat cardiovascular diseases.  
WO/2018/187342A1
Insecticidal toxins described herein are fused toxin peptides made up of a targeting domain fused to a toxin domain. The targeting peptide generates a specific association with mosquitoes by causing the fused toxin peptide to bind mosqui...  
WO/2018/187190A1
Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and method...  
WO/2018/187568A1
Disclosed are peptides comprising an insulin A chain peptide and an insulin B chain peptide, wherein the B chain peptide comprises a substitution at amino acid 10 and amino acid 20. Disclosed are methods of increasing insulin receptor ac...  
WO/2018/187317A1
A pesticidal protein class exhibiting toxic activity against Coleopteran and Lepidopteran pest species is disclosed, and includes, but is not limited to, TIC7040, TIC7042, TIC7381, TIC7382, TIC7383, TIC7386, TIC7388, and TIC7389. DNA con...  
WO/2018/187482A1
Recombinant and in vitro reconstitution methods for producing lasso peptides are provided. Methods of screening lasso peptides are also provided.  
WO/2018/185050A1
The present invention relates to a polypeptide binding to fibroblast growth factor receptor 3 iso forms 3b and 3c (FGFR3b and FGFR3c), wherein the polypeptide comprises an amino acid sequence selected from the group consisting of: (a) GV...  
WO/2018/187631A1
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endom...  
WO/2018/186702A1
The present invention relates to a multi-block copolypeptide having stimulus responsivity and surface adhesiveness. When the multi-block copolypeptide composed of an elastin-based peptide and a mussel foot protein, of the present inventi...  
WO/2018/187552A1
Aspects of the disclosure relate to compositions and methods useful for treating ocular ciliopathies, for example Leber congenital amaurosis (LCA). In some embodiments, the disclosure provides isolated nucleic acids comprising a transgen...  
WO/2018/184333A1
The present invention provides use of protein nog1 in the regulation of the plant yield and/or the grain number per ear. The amino acid sequence of the protein nog1 is as shown in sequence 2. The yield is the yield per plant, and the gra...  
WO/2018/185301A1
Cell based assays are required for the detection of biological activity and hence are required for use as potency assays, detection of neutralizing antibodies and detection and quantification of the effector cell function of therapeutic ...  
WO/2018/185080A1
The present invention relates to polypeptides and proteins comprising a fragment of a ClpB protein and compositions therefrom. The present invention also relates to the treatment and/or prevention of inflammation, in particular overweigh...  
WO/2018/185756A1
The present invention provides mutant alpha 1 -antitrypsin proteins, pharmaceutical compositions comprising the same, and methods of use thereof in treatment of subjects with an inflammatory disease or disorder.  
WO/2018/187530A1
The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compou...  
WO/2018/184107A1
Novel activators of the APC complex and methods and uses of these activators are provided. In particular, the activators are used for increasing resistance to stress and/or increasing lifespan in a plant or mammalian cell, in a plant or ...  
WO/2018/187260A1
The present disclosure relates to, inter alia, a method for treating a tumor by intratumorally delivering an effective amount of a composition comprising an expression vector that comprises a first nucleotide sequence encoding a secretab...  
WO/2018/184965A1
The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds to PD-1 and Tim-3. In addition, the invention r...  
WO/2018/187418A1
Fluorescence resonance energy transfer (FRET) constructs comprising donor and acceptor fluorophore moieties, and a peptide linking the two, which is a substrate of the endopeptidase fibroblast activation protein (FAP). Also provided are ...  
WO/2018/184477A1
Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesi...  
WO/2018/185247A1
The present invention relates to a tumor necrosis factor receptor (TNFR) binding protein complex comprising 12 or more protein ligands (PLs) that specifically bind to the extracellular part of the same TNFR. Preferably, the TNFR binding ...  
WO/2018/187791A1
Provided are cells, such as engineered cells, that express a prostate-specific membrane antigen (PSMA) or a modified form thereof. In some embodiments, the cell further contains a genetically engineered recombinant receptor, such as a ch...  
WO/2018/187182A1
Compositions, systems and methods are provided for conferring disease resistance to plant pathogens that use proteases to target plant substrate proteins inside plant cells. Briefly, the compositions, systems and methods are based upon p...  
WO/2018/184448A1
Provided is a recombinant Ganoderma lucidum immunoregulatory protein mutant having an anti-tumor effect.  
WO/2018/185244A1
The invention relates to compounds for use in the prevention and/or treatment of immunological diseases, particularly rheumatoid arthritis systemic lupus erythematosus and lupus nephritis, characterized by the subcutaneous administration...  
WO/2018/187147A1
The subject matter of this invention is directed towards insulin analogs that are stable and that are glucose-responsive. An insulin analog can be a single chain insulin (SCI). The binding affinity of insulin to the insulin receptor can ...  
WO/2018/187303A1
Polypeptides which comprises a plurality of luminescent metal binding sites and constructs comprising the polypeptides and bound luminescent metals are provided. When the constructs are exposed to suitable wavelengths of energy, the boun...  
WO/2018/187686A1
The present invention discloses a high volume manufacturing process for the production and purification of exosomes. In one embodiment, a hollow fiber perfusion reactor is used to expand stem cells. The growth media used from the stem ce...  
WO/2018/187325A1
Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, ea...  
WO/2018/178013A1
The invention relates to modified mussel adhesive proteins, to uses thereof, to nucleotide sequences encoding the modified mussel adhesive proteins, to an aminoacyl-tRNA synthetase suited for producing the modified mussel adhesive protei...  
WO/2018/183821A1
The invention features combination therapies using an IL- 15 -based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.  
WO/2018/179302A1
The present invention provides a cancer cell-specific anti-podoplanin antibody or an antigen-binding fragment thereof. The anti-podoplanin antibody is against the amino acid sequence of human podoplanin represented by SEQ ID NO: 1, the s...  
WO/2018/183671A1
Provided are conjugates of an arginine deiminase (ADI) and a Tumor Necrosis Factor (TNF) superfamily ligand, and related compositions and methods of use thereof. Also provided are conjugates of a hexameric polypeptide and a trimeric poly...  
WO/2018/183705A1
A gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency is provided comprising a plasmid or viral, e.g., an AAV, vector coding for an elastase- or cathepsin G-inhibiting, oxidation-resistant human AAT with a substitution at, fo...  
WO/2018/180204A1
The purpose of the present invention is to provide: a novel modified protein G which is capable of binding to immunoglobulin and shows a high chemical stability against an alkali solution; an affinity separation matrix comprising the mod...  
WO/2018/181903A1
The purpose of the present invention is to provide a method for producing an iPS-ML having a high interferon β productivity. Provided is a method for producing myeloid blood cells having a high interferon β productivity, said method co...  
WO/2018/178986A1
Cultures of Delftia bacteria are disclosed. Antimicrobial agents derived therefrom are also disclosed.  
WO/2018/183946A1
Transgenic silkworms stably expressing synthetic spider silk genes or composite silkworm/spider silk genes are disclosed. The exogenous spider silk genes are stably intergrated into a defined site of the fibroin heavy chain intron or a f...  
WO/2018/181638A1
Provided is a novel long-lasting adrenomedullin derivative that is capable of substantially inhibiting an undesired side reaction while maintaining the pharmacological effect of adrenomedullin. One embodiment of the present invention per...  
WO/2018/183485A1
Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequenc...  
WO/2018/178392A1
The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EX2X3X4X5X6X7EIX10X11LPNLX16RX18QYX21AFIX25X26LX28D. The pre...  
WO/2018/176144A1
ABSTRACT Provided herein are engineered nucleic acids, engineered mRNAs, engineered polypeptides, and engineered pentamerized polypeptides, human and murine, each of which include sequences of VISTA, ICOS-L, PD-L1 or B7-H4 extracellular ...  
WO/2018/181774A1
The purpose of the present invention is to provide a novel enzymatic protein that makes it possible to produce an optically active β-hydroxy amino acid. The present invention solves the aforementioned problem by providing a monooxygenas...  
WO/2018/178377A1
The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selecte...  
WO/2018/182495A1
A tolerogenic composition for use in a method of treatment for multiple sclerosis (MS) in a MS patient exhibiting T-cell autoreactivity against an endogenous epitope corresponding to a T-cell epitope comprised in the amino-acid sequence ...  
WO/2018/178666A1
This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of ...  

Matches 1 - 50 out of 152,154